Fairvalue-Calculator Fairvalue-Calculator
EN DE

Evaxion A/S, a clinical-stage biotech company, (EVAX) Fair Value & Analysis

Healthcare · US · Market cap $25.4M

Price$3.38
Fair Value$1.62
Upside-52.1%
Quality95/100
Evidence: Low Range $1.07 – $2.03

Fair value as of: Jun 25, 2026

Analysis

Evaxion A/S, a clinical-stage biotech company, (EVAX) currently trades at $3.38, while our model-based Fair Value estimate is $1.62 — implying the stock looks roughly 52.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in H…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Evaxion A/S, a clinical-stage biotech company, (EVAX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.62 versus a price of $3.38 — about −52% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EVAX?
Our 21-model fair value for Evaxion A/S, a clinical-stage biotech company, is $1.62 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.38.
What is the quality score of EVAX?
Evaxion A/S, a clinical-stage biotech company, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.